The use of anti-tuberculosis therapy for latent TB infection

References

• World Health Organization Global tuberculosis control: a short update to the 2009 report. 2009. Available from: http://www.who.int/tb/publications/global_report/2009/update/en/. Accessed March 1, 2010.
   Google Scholar
• TufarielloJChanJFlynnJLatent tuberculosis: mechanisms of host and bacillus that contribute to persistent infectionLancet Infect Dis20033957859012954564
   PubMed Web of Science ®Google Scholar
• CohnDO’BrienRTargeted tuberculin testing and treatment of latent tuberculosis infectionMMWR Morb Mortal Wkly Rep200049161
   Google Scholar
• WhiteMDuongTCruzEStrategies for effective education in a jail setting: the Tuberculosis Prevention ProjectHealth Promotion Practice20034442214611027
   PubMedGoogle Scholar
• TavitianSSpalekVBaileyRA pharmacist-managed clinic for treatment of latent tuberculosis infection in health care workersAm J Health-Sys Pharm2003601818561861
   PubMed Web of Science ®Google Scholar
• HillLBlumbergESipanCMulti-Level Barriers to LTBI Treatment: A Research NoteJ Immig Minority Health200817
   Web of Science ®Google Scholar
• An Interim Report of the Medical Research Council by their Tuberculosis Chemotherapy Clinical Trials CommitteeThe treatment of pulmonary tuberculosis with isoniazidBMJ1952273574612978309
   PubMedGoogle Scholar
• CorbettEWattCWalkerNThe growing burden of tuberculosis: global trends and interactions with the HIV epidemicArch Internal Med20031639100912742798
   PubMed Web of Science ®Google Scholar
• NarainJRaviglioneMKochiAHIV-associated tuberculosis in developing countries: epidemiology and strategies for preventionTuberc Lung Dis1992736311321
   Google Scholar
• ManosuthiWChottanapandSThongyenSSurvival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapyJAIDS20064314216885778
   PubMed Web of Science ®Google Scholar
• SwaminathanSParamasivanCKumarSUnrecognized tuberculosis in HIV-infected patients: sputum culture is a useful toolInt J TB Lung Dis200487896898
   PubMed Web of Science ®Google Scholar
• DanelCOuassaTMohRScreening for active tuberculosis before INH chemoprophylaxis in West African adults with high CD4 counts: inclusion phase of temprano ANRS 12136CROI2010216–19Montreal, Canada
   Google Scholar
• BernsteinJLottWSteinbergBYaleHChemotherapy of experimental tuberculosis. V. Isonicotinic acid hydrazide (nydrazid) and related compoundsAm Rev Tuberc195265435714903503
   PubMedGoogle Scholar
• TakayamaKWangLDavidHEffect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy197221294208567
   PubMed Web of Science ®Google Scholar
• EgsmoseTAng’awaJOPotiSJThe use of isoniazid among household contacts of open cases of pulmonary tuberculosisBull WHO1965334194335321762
   PubMed Web of Science ®Google Scholar
• EwerKMillingtonKADeeksJJDynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosisAm J Resp Crit Care Med200617483183916799072
   PubMed Web of Science ®Google Scholar
• ThompsonNEfficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on ProphylaxisBull WHO19826045555646754120
   PubMed Web of Science ®Google Scholar
• ComstockGHow much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? CounterpointInt J TB Lung Dis1999310847850
   PubMed Web of Science ®Google Scholar
• ZarHCottonMStraussSEffect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trialBMJ2007334758513617085459
   PubMed Web of Science ®Google Scholar
• le RouxSCottonMGolubJAdherence to isoniazid prophylaxis among HIV-infected children: a randomized controlled trial comparing two dosing schedulesBMC Med2009716719886982
   PubMed Web of Science ®Google Scholar
• BucherHGriffithLGuyattGIsoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trialsAIDS199913450150710197379
   PubMed Web of Science ®Google Scholar
• GrantACharalambousSFieldingKEffect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment studyJAMA200529322271915941800
   PubMed Web of Science ®Google Scholar
• NguyenTOdermattPSlesakGBarennesHRisk of latent tuberculosis infection in children living in households with tuberculosis patients: a cross sectional survey in remote northern Lao People’s Democratic RepublicBMC Infect Dis2009919619534769
   PubMed Web of Science ®Google Scholar
• MorrisonJPaiMHopewellPTuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysisLancet Infect Dis20088635936818450516
   PubMed Web of Science ®Google Scholar
• MountFFerebeeSPreventive effects of isoniazid in the treatment of primary tuberculosis in childrenNew Eng J Med196126571372114476667
   PubMed Web of Science ®Google Scholar
• World Health Organisation Guidance for national tuberculosis programmes on the management of tuberculosis in children. 2006. Available from http://www.who.int/child_adolescent_health/documents/htm_tb_2006_371/en/index.html
   Google Scholar
• ZachariahRSpielmannMHarriesAPassive versus active tuberculosis case finding and isoniazid preventive therapy among household contacts in a rural district of MalawiInt J TB Lung Dis200371110331039
   PubMed Web of Science ®Google Scholar
• CarterEMatesSTuberculosis during pregnancy. The Rhode Island experience, 1987 to 1991Chest19941065146614707956404
   PubMed Web of Science ®Google Scholar
• ScheinhornDAngelilloVAntituberculous therapy in pregnancy: risks to the fetusWest J Med19771273195198906455
   PubMedGoogle Scholar
• FranksABinkinNSniderDJrIsoniazid hepatitis among pregnant and postpartum Hispanic patientsPub Health Rep198910421512495549
   PubMed Web of Science ®Google Scholar
• MillardPWilcoskyTReade-ChristopherSWeberDIsoniazid-related fatal hepatitisWest J Med199616464864918764622
   PubMedGoogle Scholar
• OrmerodPRespiratory diseases in pregnancy. 3: Tuberculosis in pregnancy and the puerperiumBMJ2001566494499
   Google Scholar
• BoggessKMyersEHamiltonCAntepartum or postpartum isoniazid treatment of latent tuberculosis infectionObstet Gyn2000965 Pt 1757762
   Web of Science ®Google Scholar
• SniderDJrPowellKShould women taking anti-tuberculosis drugs breast-feed?Arch Int Med198414435896367682
   PubMedGoogle Scholar
• FountainFTolleyEJacobsASelfTRifampin hepatotoxicity associated with treatment of latent tuberculosis infectionAm J Med Sci2009337531732019295414
   PubMed Web of Science ®Google Scholar
• NolanCGoldbergSBuskinSHepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinicJAMA1999281111014101810086436
   PubMed Web of Science ®Google Scholar
• SaukkonenJCohnDJasmerRAn official ATS statement: hepatotoxicity of anti-tuberculosis therapyAm J Resp Crit Care Med2006174893595217021358
   PubMed Web of Science ®Google Scholar
• ByrdRHornBSolomonDGriggsGToxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patientsJAMA19792411212391241762788
   PubMed Web of Science ®Google Scholar
• StuartRWilsonJGraysonMLIsoniazid toxicity in health care workersClin Infect Dis199928489589710825056
   PubMed Web of Science ®Google Scholar
• MenziesDLongRTrajmanAAdverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trialAnn Intern Med20081491068969719017587
   PubMed Web of Science ®Google Scholar
• BrownMHowardEDeAlleaumeLAre liver function tests required for patients taking isoniazid for latent TB?J Family Pract20045316367
   Web of Science ®Google Scholar
• DevadattaSGangadharamPAndrewsRPeripheral neuritis due to isoniazidBull WHO19602358759813722334
   PubMedGoogle Scholar
• MeyerUPharmacogenetics and adverse drug reactionsLancet200035692421667167111089838
   PubMed Web of Science ®Google Scholar
• DenholmJWesselinghSChapter 135: StavudineGraysonMLMillsJKucer’s The Use of AntibioticsMelbourneHodder Arnold2010
   Google Scholar
• MaraisBGrahamSCottonMBeyersNDiagnostic and management challenges for childhood tuberculosis in the era of HIVJ Infect Dis2007196S1768517538886
   PubMed Web of Science ®Google Scholar
• SchaafHMaraisBHesselingAChildhood drug-resistant tuberculosis in the Western Cape Province of South AfricaActa Paediatrica200695552352816825130
   PubMed Web of Science ®Google Scholar
• WrightAZignolMVan DeunAEpidemiology of anti-tuberculosis drug resistance 2002–2007: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance SurveillanceLancet200936895532142215417174706
   PubMed Web of Science ®Google Scholar
• GirlingDChanSA double-blind placebo-controlled clinical trial of three anti-tuberculosis chemoprophylaxis regimens in patients with silicosis in Hong KongAm Rev Resp Dis199214536411731596
   PubMed Web of Science ®Google Scholar
• PoleskyAFarberHGottliebDRifampin preventive therapy for tuberculosis in Boston’s homelessAm J Resp Crit Care Med19961545147314778912767
   PubMed Web of Science ®Google Scholar
• ReichmanLLardizabalAHaydenCConsidering the role of four months of rifampin in the treatment of latent tuberculosis infectionAm J Resp Crit Care Med2004170883283515297274
   PubMed Web of Science ®Google Scholar
• SterlingTNew approaches to the treatment of latent tuberculosisSemin Respir Crit Care Med20082953254118810686
   PubMed Web of Science ®Google Scholar
• BurmanWJonesBTreatment of HIV-related tuberculosis in the era of effective antiretroviral therapyAm J Resp Crit Care Med2001164171211435232
   PubMed Web of Science ®Google Scholar
• MorenoSPodzamczerDBlázquezRTreatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampinAIDS20011591185118711416725
   PubMed Web of Science ®Google Scholar
• VillarinoMRidzonRWeismullerPRifampin preventive therapy for tuberculosis infection: experience with 157 adolescentsAm J Resp Crit Care Med19971555173517389154885
   PubMed Web of Science ®Google Scholar
• MitranoJSpoonerLBelliveauPExcretion of antimicrobials used to treat methicillin-resistant Staphylococcus aureus infections during lactation: safety in breastfeeding infantsPharmacotherapy20092991103110919698015
   PubMed Web of Science ®Google Scholar
• MwingaAHospMGodfrey-FaussettPTwice weekly tuberculosis preventive therapy in HIV infection in ZambiaAIDS19981218244724579875583
   PubMed Web of Science ®Google Scholar
• HalseyNCoberlyJDesormeauxJRandomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infectionLancet199835191057867929519950
   PubMed Web of Science ®Google Scholar
• GordinFChaissonRMattsJAn international, randomized trial of rifampin and pyrazinamide versus isoniazid for prevention of tuberculosis in HIV-infected personsJAMA20002831445145010732934
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and PreventionFatal severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection – New York and Georgia, 2000MMWR20015028929111330495
   PubMedGoogle Scholar
• Centers for Disease Control and PreventionUpdate: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations – United States, 2001MMWR20015073373511787580
   PubMedGoogle Scholar
• Centers for Disease Control and PreventionUpdate: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infectionMMWR Morb Mortal Wkly Rep20025199899912455909
   PubMedGoogle Scholar
• Centers for Disease Control and PreventionUpdate: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection – United States, 2003MMWR Morb Mortal Wkly Rep20035273573912904741
   PubMedGoogle Scholar
• SpyridisNSpyridisPGelesmeAThe effectiveness of a 9-month regimen of isoniazid alone versus 3-and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized studyClin Infect Dis200745671572217712755
   PubMed Web of Science ®Google Scholar
• BenatorDBhattacharyaMBozemanLRifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trialLancet2002360933252853512241657
   PubMed Web of Science ®Google Scholar
• BurmanWGallicanoKPeloquinCComparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterialsClin Pharmacokinetics2001405327341
   PubMed Web of Science ®Google Scholar
• JiBTruffot-PernotCLacroixCEffectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in miceAm Rev Resp Dis19931486 Pt 1154115468256897
   PubMed Web of Science ®Google Scholar
• van den BoogaardJKibikiGKisangaENew drugs against tuberculosis: problems, progress, and evaluation of agents in clinical developmentAntimicrobial Agents Chemotherapy2009533849862
   PubMed Web of Science ®Google Scholar
• SchechterMZajdenvergRFalcoGWeekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contactsAm J Resp Crit Care Med2006173892292616474028
   PubMed Web of Science ®Google Scholar
• KritskiAMarquesMRabahiMTransmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosisAm J Resp Crit Care Med199615313313358542139
   PubMed Web of Science ®Google Scholar
• NuermbergerETyagiSWilliamsKRifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse modelAm J Resp Crit Care Med2005172111452145616151038
   PubMed Web of Science ®Google Scholar
• AttamnaAChemtobDAttamnaSRisk of tuberculosis in close contacts of patients with multidrug resistant tuberculosis: a nationwide cohortThorax200931200964327119252032
   PubMed Web of Science ®Google Scholar
• BurgosMDeRiemerKSmallPEffect of drug resistance on the generation of secondary cases of tuberculosisJ Infect Dis2003188121878188414673768
   PubMed Web of Science ®Google Scholar
• FraserAPaulMAttamnaALeiboviciLTreatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic reviewInt J TB Lung Dis20061011923
   Web of Science ®Google Scholar
• Centers for Disease Control and PreventionTwo simultaneous outbreaks of multidrug-resistant tuberculosis – Federated States of Micronesia, 2007–2009MMWR2009581025325619300407
   PubMedGoogle Scholar
• ZiakasPMylonakisE4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicityClin Infect Dis200949121883188919911936
   PubMed Web of Science ®Google Scholar
• BrownMOAre liver function tests required for patients taking isoniazid for latent TB?J Family Prac20045316366
   Web of Science ®Google Scholar
• HollandDSandersGHamiltonCStoutJCosts and cost-effectiveness of four treatment regimens for latent tuberculosis infectionAm J Resp Crit Care Med2009179111055106019299495
   PubMed Web of Science ®Google Scholar
• AndersenPVaccine strategies against latent tuberculosis infectionTrends Microbiol200715171317141504
   PubMed Web of Science ®Google Scholar
• RepiqueCLiACollinsFMorrisSDNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on re-infection with a secondary challengeInfect Immunity20027073318332312065468
   PubMed Web of Science ®Google Scholar
• AndersenPTB vaccines: progress and problemsTrends Immunol200122316016811286732
   PubMed Web of Science ®Google Scholar
• ColditzGBrewerTBerkeyCet al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literatureJAMA199427196987028309034
   PubMed Web of Science ®Google Scholar
• TurnerJRhoadesEKeenMBelisleJFrankAOrmeIEffective pre-exposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic modeInfect Immunity20006831706170910678993
   PubMed Web of Science ®Google Scholar
• CardonaPRUTI: a new chance to shorten the treatment of latent tuberculosis infectionTuberculosis2006863–427328916545981
   PubMed Web of Science ®Google Scholar
• LambertPHawkridgeTHanekomWNew vaccines against tuberculosisClinics Chest Med2009304811826
   Web of Science ®Google Scholar
• ChurchyardGKaplanGFallowsDAdvances in immunotherapy for tuberculosis treatmentClinics Chest Med2009304769782
   Web of Science ®Google Scholar
• StickneyDNoveljicZGarsdASafety and activity of the immune modulator HE2000 on the incidence of tuberculosis and other opportunistic infections in AIDS patientsAntimicrobial Agents and Chemotherapy20075172639264117470653
   PubMed Web of Science ®Google Scholar
• RoyEStavropoulosEBrennanJTherapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in miceInfection immunity20057396101610916113331
   PubMed Web of Science ®Google Scholar
• JohnsonJSsekasanvuEOkweraARandomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosisAm J Resp Crit Care Med2003168218519112702550
   PubMed Web of Science ®Google Scholar
• JohnsonBBekkerLRickmanRrhulL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placeboTuberc Lung Dis1997783–4195203
   Google Scholar
• KedzierskaKMakJMijchAGranulocyte-macrophage colony-stimulating factor augments phagocytosis of Mycobacterium avium complex by human immunodeficiency virus type 1-infected monocytes/macrophages in vitro and in vivoJ Infect Dis1999181139039410608795
   PubMed Web of Science ®Google Scholar
• SzeligaJDanielDYangCGranulocyte – macrophage colony stimulating factor-mediated innate responses in tuberculosisTuberculosis200888172017928269
   PubMed Web of Science ®Google Scholar